Answers are grounded in this paper and cite their sources.
Pharmacovigilance study compares drug safety profiles of liposomal and conventional irinotecan, suggesting unique risks in nanomedicine.
Liposomal irinotecan(Nal-IRI) plays a crucial role as a nanomedicine in cancer treatment. Although it has clinically beneficial properties, Nal-IRI is accompanied by multiple adverse events (AEs) that require close observation. This pharmacovigilance study aimed to characterize and compare the safety profiles of liposomal irinotecan (Nal-IRI) and conventional irinotecan (IRI) using the FDA Adverse Event Reporting System (FAERS), focusing on identifying hidden risks of Nal-IRI in AEs. The data were extracted from the FAERS database (from Q1 2004 to Q3 2024). AE signals of Nal-IRI and IRI were mined by calculating reporting odds ratios (ROR), proportional reporting ratios (PRR), information component (IC) and empirical bayesian geometric mean (EBGM). A total of 90 Nal-IRI-positive PTs and 437 IRI-positive PTs were identified. Both exhibited stronger signals in gastrointestinal disorders and blood and lymphatic system disorders, and Nal-IRI also demonstrated stronger signals in the hepatobiliary disorders. We identified new specific AEs of Nal-IRI, cholangitis (ROR = 56.45), enterocolitis (ROR = 41.89), hematotoxicity (ROR = 18.47) and 302 off-label use reports. Meanwhile, Nal-IRI exhibited delayed toxicity, with a prolonged median AE onset time (35 days vs. 27 days for IRI) and fewer early reactions (≤7 days: 13.88% vs. 20.51% for IRI). Furthermore, Nal-IRI exhibited stronger signals in gastrointestinal disorders (e.g. vomiting, abdominal pain) in Asian populations, while European/American populations had stronger signals in hematological/hepatic adverse reactions (e.g. neutropenia, cholangitis). Nal-IRI demonstrates distinct safety challenges, including delayed toxicity, hepatobiliary risks, and population-specific vulnerabilities. These findings have revealed the unique risks associated with nanomedicine, underscoring the necessity extending pharmacovigilance.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: